Correction: Yagolovich et al. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma. Int. J. Mol. Sci. 2022, 23, 12687

Int J Mol Sci. 2024 May 14;25(10):5334. doi: 10.3390/ijms25105334.

Anne V Yagolovich^{1

2

3}, Alina A Isakova^{1

2}, Artem A Artykov^{1

3}, Yekaterina V Vorontsova¹, Diana V Mazur¹, Nadezhda V Antipova¹, Marat S Pavlyukov¹, Mikhail I Shakhparonov¹, Anastasia M Gileva¹, Elena A Markvicheva¹, Ekaterina A Plotnikova⁴, Andrey A Pankratov⁴, Mikhail P Kirpichnikov^{1

2}, Marine E Gasparian¹, Dmitry A Dolgikh^{1

2}

¹ Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, 117997 Moscow, Russia.
² Faculty of Biology, Lomonosov Moscow State University, 119192 Moscow, Russia.
³ Manebio LLC, 115280 Moscow, Russia.
⁴ National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, P.A. Hertsen Moscow Oncology Research Institute, 125284 Moscow, Russia.

Abstract

In the original publication [...].